Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta^® in Healthy Chinese Male Volunteers

Front Pharmacol. 2022 May 4:13:907413. doi: 10.3389/fphar.2022.907413. eCollection 2022.

Authors

Yingzi Cui¹, Dongyang Cui^{2

3}, Xinran Ren^{4

5}, Xuesong Chen⁶, Guangwen Liu¹, Zhengzhi Liu¹, Yanli Wang¹, Xinyao Qu¹, Yicheng Zhao⁵, Haimiao Yang¹

Affiliations

¹ Phase I Clinical Trial Laboratory, Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
² Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, China.
³ Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China.
⁴ School of Pharmacy, Jilin University, Jilin, China.
⁵ Clinical Medical College, Changchun University of Chinese Medicine, Jilin, China.
⁶ Jilin Province Honesty Medical Technology Consulting Co., Ltd., Jilin, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.660541.].

Keywords: SHR-1309 injection; bioequivalence; immunogenicity; perjeta®; pharmacokinetics; safety.

Copyright © 2022 Cui, Cui, Ren, Chen, Liu, Liu, Wang, Qu, Zhao and Yang.

Publication types

Published Erratum